Development of anti-HER2-targeted doxorubicin–core-shell chitosan nanoparticles for the treatment of human breast cancer

Purpose: Doxorubicin (DOX) encapsulated O-succinyl chitosan graft Pluronic(®) F127 (OCP) copolymer nanoparticles conjugated with an anti-HER2 monoclonal antibody were developed as targeted drug delivery vehicles for the treatment of HER2-overexpressing breast cancer. Methods: Five percent and 10% (w...

Descripción completa

Detalles Bibliográficos
Autores principales: Naruphontjirakul, Parichart, Viravaidya-Pasuwat, Kwanchanok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6557189/
https://www.ncbi.nlm.nih.gov/pubmed/31239670
http://dx.doi.org/10.2147/IJN.S198552

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6557189/
https://www.ncbi.nlm.nih.gov/pubmed/31239670
http://dx.doi.org/10.2147/IJN.S198552

Ejemplares similares